RemeGen’s telitacicept delivered a stronger reduction in proteinuria than placebo in a prespecified interim analysis of a phase 3 trial in high-risk IgA nephropathy. In patients with persistent proteinuria despite supportive care, 39 weeks of subcutaneous telitacicept (240 mg weekly) reduced the 24-hour urinary protein-to-creatinine ratio by −58.9% versus −8.8% with placebo, translating to a relative difference of −55.0% (P<0.001). Safety signals showed higher overall adverse-event rates with telitacicept (89.3% vs 78.6%), though serious adverse events were less frequent (2.5% vs 8.2%). The study reported no unexpected safety findings. The result reinforces the BAFF/APRIL dual-neutralization approach in IgA nephropathy and provides an early efficacy and risk snapshot ahead of further analysis and potential regulatory consideration.